Stable amyloid beta monomers and oligomers

Torleif Härd; Anders Sandberg

Stable amyloid beta monomers and oligomers

Torleif Härd (Inventor)
, Anders Sandberg (Inventor)

Department of Molecular Sciences

Publication: Patent

Abstract

The invention provides monomeric and oligomeric amyloid beta peptide isomers that are resistant towards fibrillogenesis and their use as Screening reagents or antigens in methods and pharmaceutical preparations for the treatment of Alzheimer's disease and other conditions related to protein misfolding. The alanines at positions 21 and 30, in wild type amyloid beta peptide amino acid sequence, are according to the invention replaced by cysteins, which results in an intra molecular disulphide bond. The invention further provides transgenic animals expressing modified amyloid precursor proteins or amyloid beta peptides.

Original language	English
Patent number	WO/2009/128772
IPC	PCT/SE2009/050378
Priority date	2009-10-22
Publication status	Published - 22 Oct 2009

Bibliographical note

Assignees:
HÄRD, Torleif [SE/SE]; SE (UsOnly)
SANDBERG, Anders [SE/SE]; SE (UsOnly)
MIVAC DEVELOPMENT AKTIEBOLAG [SE/SE]; Göteborg, SE (AllExceptUS)

Cite this

@misc{e57f4dd4b9b54c7f964aaf008dd0f86c,

title = "Stable amyloid beta monomers and oligomers",

abstract = "The invention provides monomeric and oligomeric amyloid beta peptide isomers that are resistant towards fibrillogenesis and their use as Screening reagents or antigens in methods and pharmaceutical preparations for the treatment of Alzheimer's disease and other conditions related to protein misfolding. The alanines at positions 21 and 30, in wild type amyloid beta peptide amino acid sequence, are according to the invention replaced by cysteins, which results in an intra molecular disulphide bond. The invention further provides transgenic animals expressing modified amyloid precursor proteins or amyloid beta peptides. ",

author = "Torleif H{\"a}rd and Anders Sandberg",

note = "Assignees: H{\"A}RD, Torleif [SE/SE]; SE (UsOnly) SANDBERG, Anders [SE/SE]; SE (UsOnly) MIVAC DEVELOPMENT AKTIEBOLAG [SE/SE]; G{\"o}teborg, SE (AllExceptUS); WO/2009/128772; PCT/SE2009/050378",

year = "2009",

month = oct,

day = "22",

language = "English",

type = "Patent",

}

TY - PAT

T1 - Stable amyloid beta monomers and oligomers

AU - Härd, Torleif

AU - Sandberg, Anders

N1 - Assignees: HÄRD, Torleif [SE/SE]; SE (UsOnly) SANDBERG, Anders [SE/SE]; SE (UsOnly) MIVAC DEVELOPMENT AKTIEBOLAG [SE/SE]; Göteborg, SE (AllExceptUS)

PY - 2009/10/22

Y1 - 2009/10/22

N2 - The invention provides monomeric and oligomeric amyloid beta peptide isomers that are resistant towards fibrillogenesis and their use as Screening reagents or antigens in methods and pharmaceutical preparations for the treatment of Alzheimer's disease and other conditions related to protein misfolding. The alanines at positions 21 and 30, in wild type amyloid beta peptide amino acid sequence, are according to the invention replaced by cysteins, which results in an intra molecular disulphide bond. The invention further provides transgenic animals expressing modified amyloid precursor proteins or amyloid beta peptides.

AB - The invention provides monomeric and oligomeric amyloid beta peptide isomers that are resistant towards fibrillogenesis and their use as Screening reagents or antigens in methods and pharmaceutical preparations for the treatment of Alzheimer's disease and other conditions related to protein misfolding. The alanines at positions 21 and 30, in wild type amyloid beta peptide amino acid sequence, are according to the invention replaced by cysteins, which results in an intra molecular disulphide bond. The invention further provides transgenic animals expressing modified amyloid precursor proteins or amyloid beta peptides.

UR - https://res.slu.se/id/publ/66724

UR - https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2009128772

M3 - Patent

M1 - WO/2009/128772

ER -

Stable amyloid beta monomers and oligomers

Abstract

Bibliographical note

Other files and links

Cite this